Yelena Y. Janjigian, MD (Moderator)
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY

R. Donald Harvey, PharmD, BCOP, FASCO, FCCP, FHOPA
Professor, Hematology and Medical Oncology and Pharmacology and Chemical Biology
Emory University School of Medicine
Medical Director, Clinical Trials Office
Director, Phase I Clinical Trials Section 
Winship Cancer Institute of Emory University
Atlanta, GA

Kelley A. Rone, DNP, RN, AGNP-c
NP Hematology/Medical Oncology
Mayo Clinic Hospital
Phoenix, AZ

Kurt A. Schalper, MD, PhD
Associate Professor of Pathology and Medicine (Medical Oncology)
Yale School of Medicine
Director, Translational Immuno-Oncology Laboratory
Yale Cancer Center
                             New Haven, CT

It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.

CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Planners/Faculty:

Yelena Y. Janjigian, MD—reports the following financial relationships:
Consultant—AbbVie Inc., AmerisourceBergen Corporation, Arcus Biosciences Inc., AskGene Pharma Inc., AstraZeneca, Basilea Pharmaceutica, Bayer, Bristol Myers Squibb Company, Daiichi Sankyo Inc., Gaurdant Health, Geneos Therapeutics, GSK, Imedex, Imugene, Lilly, Lynx Health, Merck & Co. Inc., Merck Serono, Mersana Therapeutics, Michael J. Hennessy Associates, Paradigm Medical Communications, PeerView, Pfizer Inc., Research To Practice, RGENIX, Seagen Inc., Silverback Therapeutics, and Zymeworks Inc.
Research support—Bayer, Bristol Myers Squibb Company, Cycle for Survival, Fred’s Team, Genentech Inc./Roche, Lilly, Merck & Co. Inc., National Cancer Institute (NCI), RGENIX, and the U.S. Department of Defense
Stock shareholder (direct purchase)—RGENIX

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, FASCO—reports the following financial relationships:
Consultant—Amgen Inc., Erasca, and Janssen Pharmaceuticals Inc.
Research support/funding to his institution—Abbisko Therapeutics, AbbVie Inc., ADC Therapeutics, Amgen Inc., Bayer, Bristol Myers Squibb Company, GSK, Incyte, Inhibrx Inc., Janssen Pharmaceuticals Inc., Merck & Co. Inc., Meryx, MorphoSys, Novartis Pharmaceuticals Corporation, Pfizer Inc., Sanofi, Takeda Pharmaceuticals USA Inc., Turning Point Therapeutics Inc., and Xenco

Kelley A. Rone, DNP, RN, AGNP-c—has no relevant financial relationships to disclose in relation to the content of this activity.

Kurt A. Schalper, MD, PhD—reports the following financial relationships:
Advisory board—AstraZeneca, Bristol Myers Squibb Company, EMD Serono, Genmab, Merck & Co. Inc., Molecular Templates Inc., OnCusp, Parthenon Therapeutics Inc., Shattuck Labs Inc., Takeda Pharmaceuticals USA Inc., and Torque Therapeutics/Repertoire Immune Medicines
Consultant—Agenus Inc., Clinica Alemana Santiago, Roche, and Takeda Pharmaceuticals USA Inc.
Research support—Akoya Biosciences, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly and Company, Merck & Co. Inc., Moderna Inc., Navigate BioPharma Services Inc., Pierre Fabre, Ribon Therapeutics, Roche, Surface Oncology, Takeda Pharmaceuticals USA Inc., and Tesaro/GSK
Speakers bureau—Forefront Collaborative and PeerView

Peer Reviewer:
Shirley Michelle Franks, MSN, APRN, FNP-BC—has no relevant financial relationships to disclose in relation to the content of this activity.

CEC Staff:
Katherine E. Lee, PharmD, MPH—has no relevant financial relationships to disclose in relation to the content of this activity.
David Modrak, PhD—has no relevant financial relationships to disclose in relation to the content of this activity.
Janelle Lowrey—has no relevant financial relationships to disclose in relation to the content of this activity.

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.